




Section: [13. Dermatological medicines \(topical\)](#) > [13.3. Dermatological medicines \(topical\)](#) > [Anti-inflammatory and antipruritic medicines](#)

		EMLc	ATC codes: <a href="#">D07AC01</a>
Indication	Psoriasis of unspecified type	ICD11 code: <a href="#">EA90.Z</a>	
INN	Betamethasone		
Medicine type	Chemical agent		
List type	Core		
Formulations	Local > Topical > Cream: 0.1% (as valerate) Local > Topical > Ointment: 0.1% (as valerate)		
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 2007 ( <a href="#">TRS 950</a> )		
Sex	All		
Age	Also recommended for children		
Age restriction	Hydrocortisone preferred in neonates.		
Therapeutic equivalence	Medicines within the same pharmacological class can be used		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Wikipedia	<a href="#">Betamethasone</a> 		
DrugBank	<a href="#">Betamethasone</a> 		

## Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee endorsed the inclusion of topical betamethasone valerate 0.1% (with a square box) on the core list of the EMLc. The Subcommittee also recommended including a warning about the use of more potent topical steroids in small children. An note was included in the listing stating that hydrocortisone is preferred for use in neonates.

